PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$109.41
as of June 30, 2026 -
YTD RETURNS6.97%
as of June 30, 2026 -
Total Net Assets$879.46M
as of June 30, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 2.86 | -5.42 | 2.44 | 21.68 | 13.77 | 9.85 | 7.97 | 9.88 |
| PPH (Market Price) | 2.84 | -5.46 | 2.36 | 21.72 | 13.73 | 9.84 | 7.95 | 9.95 |
| MVIS US Listed Pharmaceutical 25 Index | 2.81 | -5.56 | 2.25 | 21.37 | 13.32 | 9.46 | 7.72 | 9.68 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -6.68 | 1.08 | 1.08 | 16.72 | 12.58 | 10.67 | 8.18 | 9.90 |
| PPH (Market Price) | -7.00 | 0.69 | 0.69 | 16.33 | 12.45 | 10.57 | 8.14 | 9.95 |
| MVIS US Listed Pharmaceutical 25 Index | -6.77 | 0.94 | 0.94 | 16.36 | 12.11 | 10.28 | 7.94 | 9.70 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 06/30/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.24 |
189,036,165 |
|
NVS |
Novartis Ag |
10.63 |
99,285,725 |
|
MRK |
Merck & Co Inc |
9.85 |
91,996,363 |
|
NVO |
Novo Nordisk A/S |
5.37 |
50,139,727 |
|
ABBV |
Abbvie Inc |
4.58 |
42,745,835 |
|
PFE |
Pfizer Inc |
4.51 |
42,115,318 |
|
BMY |
Bristol-Myers Squibb Co |
4.47 |
41,760,786 |
|
GSK |
Gsk Plc |
4.42 |
41,281,169 |
|
JNJ |
Johnson & Johnson |
4.36 |
40,691,835 |
|
AZN |
Astrazeneca Plc |
4.33 |
40,488,800 |
|
MCK |
Mckesson Corp |
4.12 |
38,521,244 |
|
SNY |
Sanofi Sa/France |
4.01 |
37,413,673 |
|
COR |
Cencora Inc |
3.36 |
31,358,995 |
|
HLN |
Haleon Plc |
3.09 |
28,880,558 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
3.06 |
28,574,087 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.87 |
26,834,300 |
|
ZTS |
Zoetis Inc |
2.10 |
19,610,235 |
|
VTRS |
Viatris Inc |
1.10 |
10,232,199 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.08 |
10,098,089 |
|
AXSM |
Axsome Therapeutics Inc |
0.77 |
7,173,964 |
|
CORT |
Corcept Therapeutics Inc |
0.50 |
4,708,690 |
|
ELAN |
Elanco Animal Health Inc |
0.35 |
3,300,496 |
|
OGN |
Organon & Co |
0.23 |
2,140,904 |
|
BHC |
Bausch Health Cos Inc |
0.10 |
914,697 |
|
PRGO |
Perrigo Co Plc |
0.06 |
561,496 |
|
-USD CASH- |
-- |
-5.76 |
-53,783,061 |
|
-- |
Other/Cash |
6.22 |
58,079,573 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 05/31/2026
-
Sector
% of Net Assets -
Health Care
99.92 -
Other/Cash
0.08
Country Weightings (%) as at 05/31/2026
-
Country
% of Net Assets -
United States
62.04 -
United Kingdom
11.18 -
Switzerland
10.52 -
Denmark
5.93 -
France
4.26 -
Israel
3.30 -
Japan
2.70 -
Other/Cash
0.08
Fees
Distributions
as of 06/30/2026
Quarterly
1.85%
3.09%
1.97%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency